Secondary analysis of two placebo-controlled trials (888 participants): the minimal important difference for NT-proBNP was a 48% improvement in PAH and PH-ILD; reaching it was associated with fewer clinical worsening events in PAH (HR 0.48) and +40 m 6MWD in PH-ILD.
Secondary analysisn = 888
Lammi et al. The Minimal Important Difference in N-Terminal Pro-Brain Natriuretic Peptide in Pulmonary Hypertension